Post-marketing Observational Study Assessing the Long-term Safety of Abatacept Using a Population-based Cohort of Rheumatoid Arthritis Patients in the Province of British Columbia.

Trial Profile

Post-marketing Observational Study Assessing the Long-term Safety of Abatacept Using a Population-based Cohort of Rheumatoid Arthritis Patients in the Province of British Columbia.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Abatacept; Disease-modifying antirheumatics; Tumour necrosis factor inhibitors
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 23 Jun 2014 Planned End Date changed from 1 Aug 2018 to 1 Nov 2018 as reported by ClinicalTrials.gov record.
    • 23 Jun 2014 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018 as reported by ClinicalTrials.gov record.
    • 03 Dec 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top